Donald Trump’s CIA pick Gina Haspel is career spymaster, oversaw secret prison

Agencies
March 14, 2018

Washington, Mar 14: President Donald Trump’s pick to be the next director of the CIA is a career spymaster who oversaw torture at a secret prison during one of the darkest chapters in the agency’s history. If confirmed, 61-year-old Gina Haspel would become the first female head of the CIA. She’s described by colleagues as a seasoned veteran with 30-plus years of intelligence experience who would lead the agency with integrity. But it’s the few years she spent supervising a secret black site that will be closely scrutinized at her confirmation hearing.

Trump announced on Tuesday that he had chosen Haspel to succeed Mike Pompeo, who is replacing ousted Secretary of State Rex Tillerson. She joined the CIA in 1985 and has been deputy director of the agency since February 2017.

Between 2003 and 2005, Haspel oversaw a secret CIA prison in Thailand where terror suspects Abu Zubayadah and Abd al Rahim al-Nashiri were waterboarded, current and former U.S. intelligence officials said. Waterboarding is a process that simulates drowning and is widely considered to be a form of torture. Haspel also helped carry out an order to destroy waterboarding videos, which prompted a lengthy Justice Department investigation that ended without charges.

Trump has said that he would reintroduce waterboarding and “a lot worse,” but there’s no indication that his decision to pick Haspel signals a desire to restart the harsh interrogation and detention program. He would face steep legal and legislative hurdles if he tried.

Sen. John McCain, R-Ariz., said Haspel must explain the nature and extent of her involvement in the CIA’s interrogation program. “Current U.S. law is clear in banning enhanced interrogation techniques,” said McCain, who was beaten as a prisoner during the Vietnam War. “Any nominee for director of the CIA must pledge without reservation to uphold this prohibition.”

Former CIA Director John Brennan declined to say what Haspel’s exact role was in the interrogation program, but he told NBC that she has a “lot of integrity” and has tried to carry out her agency duties “when asked to do difficult things in challenging times.”

Brennan predicted she would be confirmed. “Gina is a very competent professional who I think deserves the chance to take the seat,” he said. Senator Richard Burr, R-N.C., the chairman of the Senate intelligence committee, which will vote whether to confirm Haspel, said she has the “right skill set, experience and judgment” to lead the CIA.

Human rights advocates said they opposed Haspel’s promotion to the helm of the CIA. “No one who had a hand in torturing individuals deserves to ever hold public office again, let alone lead an agency,” Human Rights First’s Raha Wala said Tuesday. “To allow someone who had a direct hand in this illegal, immoral and counterproductive program is to willingly forget our nation’s dark history with torture.”

After Haspel was named deputy CIA director, the European Center for Constitutional and Human Rights asked German prosecutors to issue a warrant for her arrest over her role in the interrogations. Federal prosecutors never issued the warrant because the case lacked a connection to Germany. But the rights group’s allegations against Haspel remain part of a preliminary investigation that German authorities could revive if they receive evidence that any of the parties have links to Germany.

Last year, Haspel’s name came up during a civil lawsuit in Spokane, Washington, filed by three men who said they suffered waterboarding, beatings and sleep deprivation in the CIA interrogation program developed by former Spokane psychologists James E. Mitchell and Bruce Jessen.

Lawyers for the psychologists wanted to interview Haspel and another CIA official involved in the program, but government lawyers told the federal judge in the case that the officials and documents were protected under the state secrets privilege and making them public would threaten national security.

Haspel has been chief of station at CIA outposts abroad. In Washington, she has held several senior leadership positions, including deputy director of the National Clandestine Service.

In her current post, she worked with Pompeo to manage intelligence collection, analysis, covert action, counterintelligence and cooperation with the CIA’s foreign counterparts. In a brief statement, the former undercover officer said she was “humbled” by Trump’s confidence in her to lead the agency.

Comments

Linda Peters
 - 
Wednesday, 14 Mar 2018

I had ever read. I hope it will help a lot for all. Thank you so much for this amazing posts and keep update like this excellent article.

 

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
May 30,2020

May 30: Warning of the tightrope walk ahead as governments battle the coronavirus crisis, Nobel laureate Peter Charles Doherty has expressed concern about densely populated countries such as India relaxing lockdown norms while also describing a complete shutdown as “an economic and social impossibility”.

The Australian immunologist, who cautioned that the number of COVID-19 cases will rise in the coming days, said the earliest time frame for an effective vaccine “going into large numbers of people” is nine to 12 months.

"If all goes well with testing, we could know if some of the candidate vaccines are both safe and effective as early as September/October. Then, rolling a vaccine out will depend on the type of product and how quickly it can be made, put in vials and so forth," Doherty told PTI in an email interview from Melbourne.

The novel coronavirus, he added, does not change fast like influenza and, from what is known so far, “the same vaccine should work everywhere”.

Doherty, who is with the Department of Microbiology and Immunology at the Doherty Institute, University of Melbourne, won the Nobel Prize for Medicine in 1996 for his discovery of how the body’s immune system distinguishes virus-infected cells from normal ones.

Discussing the lockdown, he said, "If it was purely a matter of hard science, everywhere should stay locked down. But that’s pretty much an economic and social impossibility.”

The expectation, he said, is the numbers will rise and limiting spread will depend on people acting responsibly and the capacity for rapid response and extensive contact testing.

“And in a densely populated country like India I think that it will be very difficult," the scientist said.

Several countries, including India, began relaxing lockdown norms in mid-May despite the WHO’s warning about a second wave. India’s lockdown began on March 25 and has since been extended. The fourth phase ends on Sunday.

Asked whether there are any alternatives to a lockdown, the 79-year-old said, "There is no other option other than closing borders. South Korea, for example, conducted massive, intensive testing and contact tracing in a wealthy country with a very disciplined population. Otherwise, not till we have effective vaccines."

He added that he personally doesn’t see the point of closing borders for people coming in if there’s already a high incidence of disease in the community, “unless it’s to avoid the need to care for them and use scarce hospital beds".

According to Doherty, the coronavirus "is a new virus which has come straight out of nature".

“It (the virus) has moved so rapidly across the world because of people travelling on international planes as well as tourist ships," he added.

The immunologist also warned against the use of hydroxychloroquine to treat COVID-19, and said current and planned trials of the anti-malaria drug should be stopped.

“My understanding is that the use of the drug in severe disease is definitely contra-indicated, but it’s not yet clear whether, if taken under medical supervision, it could have some useful effect if taken early on, or as a preventive. Those trials just haven’t been done properly," Doherty noted.

The Indian Council of Medical Research (ICMR) has backed the use of hydroxychloroquine as a preventive against COVID-19 even after the WHO suspended clinical trials of the drug citing safety concerns.

Asked whether plasma therapy can be an effective treatment for COVID-19, Doherty said, "We lack good properly controlled trials but, especially if the plasma has been tested for antibody levels and there’s evidence of good activity, it could be helpful. If I had the disease and was offered plasma therapy I would certainly accept, but I would not take hydroxychloroquine."

Doherty is also very optimistic about herd immunity developing against the SARS-CoV-2 infection.

"We think that (herd immunity) will cut in and have an obvious effect when, say, 60 per cent of people have been infected. Best hope is to boost herd immunity with a vaccine," he stated.

Herd immunity is a form of indirect protection from infectious disease that occurs when a large percentage of a population has become immune to an infection, whether through vaccination or previous infections.

The number of COVID-19 cases have crossed 5.9 million and the fatalities 3,65,000, according to the Johns Hopkins University on Saturday. 

In India, the death toll has risen to 4,971 and the number of cases to 1,73,763, according to the Union Health Ministry on Saturday.

Several states, including Bihar, Uttar Pradesh, Madhya Pradesh, Jharkhand and Chhattisgarh, have reported a rise in number since lockdown norms were relaxed in early May and migrant workers reached home.

In Uttar Pradesh, for instance, the number of infections rose from around 3,000 on May 4 to 6,532 on May 26. Similarly, Bihar’s numbers increased from around 500 to over 2,700 in the period.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
April 10,2020

Paris, Apr 10: French pharma major Sanofi said on Friday it has decided to donate 100 million doses of hydroxychloroquine, the anti-malaria drug which could be a potential weapon against novel coronavirus, across 50 countries.

The company has already doubled its incremental production capacity on top of the usual production for current indications across its eight hydroxychloroquine manufacturing sites worldwide and is on track to quadruple it by the summer.

"In this global health emergency, Sanofi stands ready to assist as many countries as possible, starting with countries where its medicine is registered for current approved indications as well as countries where there are no hydroxychloroquine suppliers or countries with underserved populations," it said in a statement.

Sanofi called for coordination among the entire hydroxychloroquine chain worldwide to ensure the continued supply of the medicine if proven to be a well-tolerated and effective treatment in COVID-19 patients.

"The COVID-19 pandemic is an unprecedented health and economic crisis which is shaking some of the very fundamentals of international solidarity and cooperation among countries," said Chief Executive Officer Paul Hudson. "This virus does not care about the concept of borders, so we should not either," he added.

"It is critical that international authorities, local governments, manufacturers and all other players involved in the hydroxychloroquine chain work together in a coordinated manner to ensure all patients who may benefit from this potential treatment can access it. If the trials prove positive, we hope our donation will play a critical role for patients," said Hudson.

While hydroxychloroquine is generating a lot of hope for patients around the world, said Sanofi, it should be remembered that there are no results from ongoing studies and the results may be positive or negative.

To date, there is insufficient clinical evidence to draw any conclusion over the safety and efficacy of hydroxychloroquine in the management of COVID-19 patients.

It is one of several medicines being investigated by the World Health Organisation (WHO) in its international clinical trial seeking a treatment solution for COVID-19. "Sanofi is supporting ongoing trials by providing the medicine to some participating investigator sites and other independent research centres," it said.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
April 12,2020

Apr 12: Pope Francis called on Sunday for an "immediate" ceasefire in global conflict and urged European nations to show "solidarity" in the face of a coronavirus pandemic that has claimed more than 109,000 lives worldwide.

"May Christ our peace enlighten all who have responsibility in conflicts, that they may have the courage to support the appeal for an immediate global ceasefire in all corners of the world," the pope said in a livestreamed Easter message.

Francis added that it was time for Europe, which he described as his "beloved continent", to "rise again, thanks to a concrete spirit of solidarity" similar to that shown after World War II.

Christians around the world are marking a solitary Easter, forced to celebrate the most joyful day in the Christian calendar largely alone amid the sorrowful reminders of the devastation wrought by the coronavirus pandemic

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.